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The t(11;14)(q13;q32) translocation is seen in 15%-20% patients with multiple myeloma (MM). It generally is
not associated with worse outcomes. We studied the impact of t(11;14)(q13;q32) on outcome in patients with
MM who received high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation
(auto-HCT). Eligible patients underwent high-dose chemotherapy followed by auto-HCT at the M.D. Anderson
Cancer Center between February 2000 and August 2010, and had conventional cytogenetic (CC) or ﬂuores-
cence in situ hybridization (FISH) results available before auto-HCT (n ¼ 993). The cohort was divided into 3
groups of patients: (1) normal (diploid by CC and negative by FISH; n ¼ 869); (2) t(11;14)(q13;q32) by CC or
FISH (n ¼ 27); and (3) high-risk (HR) abnormalities by CC or FISH (n ¼ 97). Of the 27 patients with
t(11;14)(q13;q32), 18 had isolated t(11;14)(q13;q32) and 9 had concurrent HR abnormalities. The primary
objective was to compare outcomes in patients with t(11;14)(q13;q32) and patients with diploid or HR
markers detected by CC or FISH studies. The median duration of follow-up in surviving patients was
37 months. The 3-year progression-free survival (PFS) was 47% for the normal group, 27% for the
t(11;14)(q13;q32) group, and 13% for the HR group (P < .00001). The 3-year OS was 83% for the normal group,
63% for the t(11;14)(q13;q32) group, and 34% for the HR group (P < .00001). On multivariate analysis,
t(11;14)(q13;q32) and HR abnormalities by CC or FISH and relapsed disease at auto-HCT were associated with
shorter PFS, whereas t(11;14)(q13;q32) and HR abnormalities by CC or FISH, b2 microglobulin of >3.5, and
relapsed disease at the time of auto-HCT were associated with shorter OS. In conclusion, patients with
t(11;14)(q13;q32) had worse outcomes than patients with normal CC or FISH studies, but better outcomes
than patients with HR markers detected by CC or FISH studies.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION a subset of patients with del 17p [10]. Based on these prelimi-
Multiple myeloma (MM) accounts for approximately 1%
of all cancers and approximately 10% of hematologic
malignancies in the United States [1,2]. Routine conventional
cytogenetic (CC) analyses and interphase ﬂuorescence in
situ hybridization (FISH) are helpful in stratifying patients
with MM into high-risk (HR) or standard-risk disease cate-
gories [3-5]. Deletion of 13q ormonosomy 13 and hypoploidy
by CC and of t(4;14)(p16.3;q32), t(14;16)(q32;q23),
t(14;20)(q32;q11.2), and del17p13 by CC or FISH are consid-
ered HR abnormalities [5-8]. Approximately 15% of patients
with symptomatic myeloma have HR disease, and their
median overall survival (OS) even with optimal therapy is
approximately 2-3 years [7,8].
Recent trials incorporating bortezomib as part of induction
regimens have shown signiﬁcantly improved outcomes in
patients with t(4;14), which is now considered an
intermediate-risk abnormality by some investigators [9-11]. In
the Dutch-Belgian Hemato-Oncology Cooperative Group
(HOVON), the use of bortezomib before and after autologous
hematopoietic stem cell transplantation (auto-HCT) was asso-
ciated with longer progression-free survival (PFS) and OS indgments on page 1231.
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nowconsidered thepreferred therapy forpatientswithHRMM.
The t(11;14)(q13;q32) abnormality involving IgH and
CCND-XT genes occurs in approximately 15%-20% of patients
with newly diagnosed MM [12-14]. Previous studies have
shown that t(11;14)(q13;q32) is associated with non-
secretory myeloma, IgM or IgE monoclonal protein [14,15],
lymphoplasmacytic or small mature plasma cell morphology,
and CD20 expression [15-19]. The presence of
t(11;14)(q13;q32) generally is not associated with worse
outcome in MM [13,20-22]; however, data on the prognostic
signiﬁcance of t(11;14)(q13;q32) in the context of autologous
stem cell transplantation (auto-HCT) are limited [21]. In this
study, we evaluated the impact of t(11;14)(q13;q32) on
outcomes in patients with MM who underwent auto-HCT at
our institution, and compared these outcomes with those of
patients with diploid CC or negative FISH ﬁndings and of
patients with HR markers detected by CC or FISH.
MATERIALS AND METHODS
Patients
We performed a retrospective chart review of patients with symptom-
atic MM who underwent high-dose chemotherapy followed by auto-HCT at
the M.D. Anderson Cancer Center between February 2000 and August 2010.
Patients who had CC or FISH results available at any point before undergoing
auto-HCT were eligible for the study. Translocation t(11;14)(q13;q32) was
deﬁned as an abnormal signal pattern detected in at least 2 metaphases byTransplantation.
Table 1
Patient Characteristics
Characteristic Overall (n ¼ 993) Normal (n ¼ 869) HR (n ¼ 97) t(11; 14) (n ¼ 27) P Value
Normal
versus HR
Normal versus
t(11;14)
Sex, n (%)
Male 564 (57) 494 (57) 55 (57) 15 (56) .90 .90
Female 429 (43) 375 (43) 42 (43) 12 (44)
Age, yrs, median (range) 58 (29-80) 57 (29-80) 58 (31-75) 59 (44-72)
Age group, n (%)
65 yrs 820 (83) 721 (83) 77 (79) 22 (81) .40 .50
>65 yrs 173 (17) 148 (17) 20 (21) 5 (19)
Yr of auto-HCT, n (%)
2005 421 (42) 374 (43) 41 (42) 6 (22) .90 .02
>2005 572 (58) 495 (57) 56 (58) 21 (78)
Time from diagnosis to auto-HCT
Months, median (range) 7.8 (1.7-262.8) 7.9 (1.7-262.8) 7.7 (2.1-65.7) 6.6 (3.3-60.5)
6 mo, n (%) 330 (33) 287 (33) 34 (35) 9 (33) .70 .60
>6 mo, n (%) 662 (67) 581 (67) 63 (65) 18 (67)
Unknown, n 1 1
Previous auto-HCT, n (%)
0 950 (96) 832 (96) 92 (95) 26 (96) .40 .70
1 41 (4) 35 (4) 5 (5) 1 (4)
2 1 (0) 1 (0) 0 (0) 0 (0)
Unknown 1 1
Beta-2 microglobulin at diagnosis
Median (range) 3.3 (0.5-40) 3.07 (0.5-40) 4.9 (2-33.1) 5.1 (1.4-21.2)
3.5, n (%) 373 (56) 345 (59) 22 (34) 6 (27)
3.5-5.5, n (%) 130 (19) 109 (19) 15 (23) 6 (27)
>5.5, n (%) 167 (25) 129 (22) 28 (43) 10 (45)
Unknown, n 323 286 32 5
Beta-2 microglobulin at auto-HCT
Median (range) 2.6 (1.2-40) 2.6 (1.2-40) 3 (1.6-23.2) 2.7 (1.5-6.9)
3.5, n (%) 688 (75) 606 (76) 62 (67) 20 (80) .05 .40
3.5-5.5, n (%) 141 (15) 124 (16) 14 (15) 3 (12)
>5.5, n (%) 86 (9) 67 (8) 17 (18) 2 (8)
Unknown, n 78 72 4 2
Disease status at auto-HCT, n (%)
Relapse 148 (15) 110 (13) 36 (37) 2 (7) <.001 .30
Other 845 (85) 759 (87) 61 (63) 25 (93)
Response before auto-HCT, n (%)
CR/VGPR/PR 805 (81) 711 (82) 69 (71) 25 (93)
MR/SD/PD/NR 181 (18) 151 (17) 28 (29) 2 (7) .007 .10
NE 7 (1) 7 (1) 0 (0) 0 (0)
Stem cell source, n (%)
Bone marrow 3 (0) 2 (0) 0 (0) 1 (4) .80 .09
Peripheral blood 990 (100) 867 (100) 97 (100) 26 (96)
Melphalan alone, n (%)
Yes 824 (83) 720 (83) 80 (82) 24 (89) .90 .30
No 169 (17) 149 (17) 17 (18) 3 (11)
Novel agent, n (%)
Yes 668 (67) 573 (66) 74 (76) 21 (78) .04 .20
No 325 (33) 296 (34) 23 (24) 6 (22)
CR indicates complete response; MR, minimal response; NE, not evaluable; NR, no response; PD, progressive disease; PR, partial response; SD, stable disease;
VGPR, very good partial response.
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FISH. HR cytogenetic abnormalities were deﬁned as del(13q)/-13 or
hypoploidy by CC only, or t(4;14)(p16.3;q32), t(14;16)(q32;q23),
t(14;20)(q32;q11.2) or del(17p13) by CC or FISH [5-7]. Normalwas deﬁned as
diploid by CC and negative by FISH at each time point before auto-HCT.
Response and Outcome
Response criteria were as deﬁned by the International Myeloma
Working Group (IMWG) uniform response criteria [23]. PFS was deﬁned as
the time from the day of auto-HCT to the date of disease progression or
death [24]. OS was deﬁned as the time from the day of auto-HCT to the date
of death from any cause.
Statistical Analysis
The primary objective of this study was to compare the rates of PFS and
OS in patients with t(11;14)(q13;q32) to those with normal or HR CC or FISH
studies. PFS was deﬁned as the time from transplantations to either disease
progression or death, and OS was deﬁned as the time from transplantations
to death from any cause. Patients whowere alive at the time of analysis werecensored on the date of the last follow-up. Actuarial estimates of PFS and OS
were calculated using the Kaplan-Meier method [25]. Cox proportional
hazards regression analysis was used to evaluate the impact of various risk
factors, including t(11;14)(q13;q32), on PFS and OS. Factors considered
included age, sex, year of auto-HCT, interval between diagnosis and auto-
HCT, CC or FISH abnormalities, b2 microglobulin level at diagnosis and at
auto-HCT, disease status at auto-HCT, response to induction, previous auto-
HCT, and previous use of novel agents. Statistical signiﬁcance was deﬁned at
the 0.05 level, and factors signiﬁcant on univariate analysis were considered
in multivariate analyses. Statistical analyses were performed using Stata 9.0
(StataCorp, College Station, TX).
RESULTS
Patient Characteristics
We identiﬁed 993 patients with MM and CC and FISH as
described above who underwent auto-HCT at our institution
between February 2000 and August 2010. Patient charac-
teristics are summarized in Table 1. Of these 993 patients,
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Figure 1. Probabilities of Progression-Free Survival and Overall Survival.
K. Sasaki et al. / Biol Blood Marrow Transplant 19 (2013) 1227e1232 1229869 had normal CC or FISH results, 27 had t(11;14)(q13;q32),
and 97 had HR abnormalities detected by CC or FISH. Patients
in the 3 groups were fairly evenly matched. Overall, 15% of
the patients had relapsed disease at auto-HCT, including 13%
in the normal group, 37% in the HR group, and 7% in the
t(11;14)(q13;q32) group.
CC data were available for all 27 patients with
t(11;14)(q13;q32), whereas FISH datawere available for only
19 of these 27 patients. The t(11;14)(q13;q32) was detected
by CC in only 13 of the 19 patients with IgH/CCND1-XT
rearrangement (68%), reinforcing the greater sensitivity of
FISH in detecting this abnormality. Overall, 21 of 27 patients
had t(11;14)(q13;q32) detected by CC. Of the 21 patients
with this abnormality, 5 (24%) had a hyperdiploid clone, 9
(43%) had a hypodiploid clone, and 7 (33%) had a pseudodi-
ploid clone. Eighteen of the 27 patients (67%) with
t(11;14)(q13;q32) had either an isolated t(11;14)(q13;q32)
abnormality or another non-HR abnormality. Nine patients
(33%) had at least 1 HR abnormality, with t(11;14)(q13;q32)
plus del(13q) in 7 patients (26%) and t(11;14)(q13;q32)
plus del(13q) and del(17p13) in 2 patients (7%). Bone
marrow ﬂow cytometry analyses detected CD20 expres-
sion on plasma cells in 3 of the 27 patients (11%) with
t(11;14)(q13;q32).
Eighty-nine of the 97 patients with HR abnormalities
(92%) had del(13q) alone or in combination with other HR
abnormalities. Four patients (4%) had del(17p13) alone, and 4(4%) had t(4;14)(p16.3;q32), t(14;16)(q32;q23), or
t(14;20)(q32;q11.2).
Induction Therapy and Preparative Regimen
Disease status and responses to previous induction
therapy are summarized in Table 1. Novel agents, including
thalidomide, lenalidomide, and bortezomib, were used for
induction or salvage before auto-HCT in 573 patients (66%)
with normal CC or FISH, in 21 patients (78%) with
t(11;14)(q13;q32), and in 74 patients (76%) with HR detected
by CC or FISH (Table 1). Melphalan alone was used as
preparative regimen for 720 patients (83%) in the normal
group, 24 patients (89%) in the t(11;14)(q13;q32) group, and
80 patients (82%) in the HR group.
Survival
The median duration of follow-up in the surviving
patients was 37 months (range, 1 to 130 months). Accord-
ingly, outcomes were compared within 3 years after allo-
HCT. The median PFS was 33 months for the normal group,
23 months for the t(11;14)(q13;q32) group, and 9.7 months
for the HR group (Figure 1A). The 3-year PFS was 47% for the
normal group, 27% for the t(11;14)(q13;q32) group, and 13%
for the HR group [normal versus t(11;14)(q13;q32), P ¼ .02;
t(11;14)(q13;q32) versus HR, P¼ .05] (Figure 1A). Themedian
OS was 87 months for the normal group, 51 months for the
t(11; 14)(q13; q32) group, and 21 months for the HR group
(Figure 1B). The 3-year OSwas 82% for the normal group, 63%
for the t(11;14)(q13;q32) group, and 34% for the HR group
[normal versus t(11;14)(q13;q32), P ¼ .01; t(11;14)(q13;q32)
versus HR, P ¼ .04] (Figure 1B). Median PFS and OS showed
similar trends when patients with relapsed disease at auto-
HCT were excluded from the survival anlyses (P < .0001 for
both PFS and OS).
On univariate analyses, t(11;14)(q13;q32), HR abnormal-
ities detected by CC or FISH, b2 microglobulin of >3.5 at
either diagnosis or auto-HCT, relapsed disease at auto-HCT,
<partial response (PR) at auto-HCT, and induction therapy
without novel agents were associated with signiﬁcantly
shorter PFS and OS (Table 2). Because of the large proportion
of patients with unknown b2 microglobulin values at diag-
nosis, this variable was not considered in multivariate anal-
ysis despite its statistical signiﬁcance on univariate analysis.
On multivariate analysis, t(11;14)(q13;q32) and HR abnor-
malities detected by CC or FISH and relapsed disease at auto-
HCT were independently associated with shorter PFS. On
multivariate analysis for OS, t(11;14)(q13;q32) and HR
abnormalities detected by CC or FISH, b2 microglobulin >3.5,
and relapsed disease at auto-HCT were independently asso-
ciated with shorter OS (Tables 3 and 4).
DISCUSSION
This retrospective analysis shows that patients with MM
carrying t(11;14)(q13;q32) detected by CC or FISH had
intermediate PFS and OS compared with patients with
normal or HR CC or FISH results before auto-HCT. Although
this translocation is frequently seen in MM, there are con-
ﬂicting data regarding its clinical implications. Several
studies have studied the impact of t(11;14)(q13;q32) on
outcome in patients with MM [4-7,12-21]. Fonseca et al. [13]
reported on 336 patients with newly diagnosedMM enrolled
in the Eastern Cooperative Oncology Group (ECOG) trial,
E9486. They identiﬁed 53 patients (16%) with
t(11;14)(q13;q32) detected by FISH. Patients with the
t(11;14)(q13;q32) appeared to have better survival and
Table 2
Univariate Analysis
Median followup in Alive (n ¼ 670) Overall
(n ¼ 993)
OS PFS
Outcomes at 3 Yrs Died HR (95% CI) P Value Progression/died HR (95% CI) P Value
Normal 869 124 Reference 388 Reference
HR 97 53 5.96 (4.3-8.3) <.001 78 3.45 (2.7-4.4) <.001
t(11;14) 27 7 2.7 (1.2-5.7) .01 14 1.9 (1.1-3.2) .02
Sex
Male 564 109 276
Female 429 75 0.9 (0.7-1.2) .60 204 1.02 (0.85-1.2) .80
Age
65 yrs 820 152 399
>65 yrs 173 32 1.1 (0.8-1.6) .60 81 1.05 (0.8-1.3) .70
Yr of auto-HCT
2005 421 89 241
>2005 572 95 1.2 (0.9-1.6) .20 239 0.99 (0.8-1.2) .90
Time from diagnosis to auto-HCT
6 mo 330 47 153
>6 mo 662 136 1.5 (1.1-2.1) .02 326 1.1 (0.9-1.4) .20
Unknown 1
Number of previous auto-HCTs
0 950 174 0.7 (0.4-1.4) .30 460 1.1 (0.7-1.7) .80
1 41 9 18
2 1 1 1
Unknown 1
Beta-2 microglobulin at auto-HCT
3.5 688 102
3.5-5.5 141 33 1.6 (1.1-2.4) .01 320 1.2 (0.9-1.5) .20
>5.5 86 31 2.8 (1.9-4.2) <.001 72 1.4 (1.04-1.9) .02
Unknown 78
3.5 versus >3.5 0.5 (0.4-0.7) <.001 0.8 (0.6-0.9) .035
>5.5 versus 5.5 1.4 (1.02-1.9) .03
Disease atatus at allo-HCT
Relapse 148 57 3.2 (2.3-4.4) <.001 107 2.5 (2.0-3.11) <.001
Other 845 127 373
Response before allo-HCT
CR/VGPR/PR 805 127 373
MR/SD/PD/NR 181 52 1.8 (1.3-2.5) <.001 102 1.3 (1.06-1.6) .01
NE 7 5 excld 5 excld
Melphalan alone
Yes 824 143 0.85 (0.6-1.2) .40 377 0.8 (0.7-1.01) .07
No 169 41 103
CR indicates complete response; MR, minimal response; NE, not evaluable; NR, no response; PD, progressive disease; PR, partial response; SD, stable disease;
VGPR, very good partial response.
K. Sasaki et al. / Biol Blood Marrow Transplant 19 (2013) 1227e12321230response to treatment, although the difference did not reach
statistical signiﬁcance. The patients in that study did not
receive auto-HCT and novel agents, however.
Dewald et al. [20] compared the clinical efﬁcacy of
metaphase CC and FISH with interphase FISH in 154 patients
with newly diagnosed MM. They found increased detection
of chromosomal abnormalities with interphase FISH (86%)
compared with metaphase CC or FISH (40%). In that study,
the presence of t(11;14)(q13;q32) detected by CC was asso-
ciated with intermediate outcomes in terms of OS between
normal CC and HR CC; however, detection of
t(11;14)(q13;q32) by interphase FISH was not associated
with adverse outcomes [20].Table 3
Multivariate Analysis for PFS
Overall
(n ¼ 993)
PFS Multivariate Analysis
HR 95% CI P Value
Normal 869
HR 97 2.9 2.2-3.7 <.001
t(11;14) 27 2 1.2-3.4 .01
Disease status at transplantation
Relapse 148 1.96 1.5-2.5 <.001
Other 845Moreau et al. [21] reported the impact of recurrent 14q32
translocations on outcomes in 168 patients with newly
diagnosed MM enrolled between January 1995 and
December 2000 with a median follow-up of 27 months. All
168 patients underwent at least 1 auto-HCT, and 10 patients
also underwent allogeneic HCT. The authors identiﬁed 26
patients (15.5%) with t(11;14)(q13;q32) by interphase FISH.
The patients with t(11;14)(q13;q32) had better survival
compared with those without this abnormality [21].
Gertz et al. [26] evaluated the clinical implications of
t(11;14)(q13;q32) in patients with MM treated with high-
dose therapy, and found no survival difference in patients
with and without t(11;14)(q13;32). In another study, 1064
patients with newly diagnosed MM enrolled in the Inter-
groupe Francophone duMyélome 99 trials were screened for
chromosomal aberrations frequently seen in MM, and
t(11;14)(q13;q32) was detected in 21%. The majority of these
patients underwent auto-HCT, and 65 underwent allogeneic
HCT. The presence of t(11;14)(q13;q32) had no adverse affect
on survival [27].
In our study, the patients in the t(11;14)(q13;q32) group
had an intermediate outcome between those in the normal
and HR by CC or FISH groups. We also compared patients
with t(11;14)(q13;q32) only (18 of 27) and those with
t(11;14)(q13;q32) plus other HR abnormalities (9 of 27) with
Table 4
Multivariate Analysis for OS
Overall (n ¼ 993) OS Multivariate Analysis
HR 95% CI P Value
Normal 869
HR 97 4.6 3.2-6.6 <.001
t(11;14) 27 3.1 1.4-6.7 .004
Beta-2 microglobulin at study enrollment
3.5 versus >3.5 0.6 0.4-0.8 .001
>5.5 versus 5.5
Disease status at transplantation
Relapse 148 2.2 1.5-3.1 <.001
Other 845
K. Sasaki et al. / Biol Blood Marrow Transplant 19 (2013) 1227e1232 1231the normal and HR by CC or FISH groups in a multivariate
model. When analyzed separately, both t(11;14)(q13;q32)
alone and t(11;14)(q13;q32) with other HR abnormalities
were predictive of signiﬁcantly shorter PFS, whereas
t(11;14)(q13;q32) showed only a strong trend toward shorter
OS.
Our results are consistent with earlier reports of worse
outcomes in patients with any CC abnormality, regardless of
risk category, compared with patients with normal karyo-
type [5,20,28]. This may be a function of higher proliferation
in the cells in which a karyotypic abnormality is detected
[21]. Furthermore, the relatively worse outcomes of patients
with t(11;14)(q13;q32) in the present study could be related
to our inclusion of patients with relapsed disease at auto-HCT
(15%) or with concurrent HR abnormalities (33%). Using gene
expression proﬁling, Nair et al. [29] categorized patients with
t(11;14)(q13;q32) into 2 subsets. The subset with CD20
expressionwas associatedwith a durable remission, whereas
the subset lacking CD20 expression had a shorter duration of
remission. The fact that almost 90% of our patients with
t(11;14)(q13;q32) lacked CD20 expression might have been
partially responsible for the worse outcomes.
Other signiﬁcant prognostic markers were a high b2
microglobulin level at auto-HCT and relapsed disease at
auto-HCT, both of which are known risk factors for worse
outcomes in MM [30-33]. Elevated b2 microglobulin level
either at diagnosis or at auto-HCT has been associated with
worse outcome in several previous studies and retrospective
analyses. Similarly, it is well known that patients undergoing
auto-HCT after relapse have signiﬁcantly shortened PFS
and OS.
There are several potential limitations to consider when
interpreting the results of the present study. These include
the study’s retrospective nature, heterogeneous patient
population in terms of disease status and non-
transplantations therapy, relatively small number of patients
with t(11;14)(q13;q32), and concurrent HR abnormalities
detected by CC or FISH in approximately one-third of the
patients with t(11;14)(q13;q32).
In summary, the present study shows that patients with
t(11;14)(q13;q32) had intermediate outcomes compared
with normal patients and patients with HR abnormalities
detected by CC or FISH. This ﬁnding may be used to stratify
patients into risk categories and help predict outcome.ACKNOWLEDGMENTS
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